| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f7f2b4e5865e08c4b8590d51cd56145 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-36 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-415 |
| filingDate |
2002-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a668cd49555d961799618bc66d66189c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_163e808fd38ba9674cd1d7d504b717cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6eb3c24b2ecfde3938066cbd0d8af1e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03d800799f20e4a66a7fe4c2bfc54848 |
| publicationDate |
2004-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1434793-A1 |
| titleOfInvention |
RECOMBINANT ALLERGEN WITH REDUCED IgE BINDING BUT UNDIMINISHED T-CELL ANTIGENICITY |
| abstract |
The present invention relates generally to reagents useful in the immunotherapeutic or immunoprophylactic treatment of allergic diseases. More particularly, the present invention provides modified allergens exhibiting reduced IgE interactivity including reduced IgE production-stimulatory activity, while retaining T-cell antigenicity, which are useful in the immunomodulation of type I allergic disease conditions. The present invention further contemplates a method of immunomodulation of allergic diseases such as type I allergic disease conditions by the administration of modified allergens exhibiting reduced IgE interactivity while retaining T-cell antigenicity. |
| priorityDate |
2001-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |